ACORN BIOVENTURES, L.P. 13D and 13G filings for Cardiff Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-06 4:01 pm Sale | 2023-12-31 | 13G | Cardiff Oncology, Inc. CRDF | ACORN BIOVENTURES, L.P. | 1,946,762 4.200% | -1,096,411 (-36.03%) | Filing |
| 2023-01-26 1:30 pm Unchanged | 2023-01-26 | 13G | Cardiff Oncology, Inc. CRDF | ACORN BIOVENTURES, L.P. | 3,043,173 6.380% | 0 (Unchanged) | Filing |
| 2023-01-26 1:28 pm Sale | 2022-09-13 | 13D | Cardiff Oncology, Inc. CRDF | ACORN BIOVENTURES, L.P. | 3,043,173 6.380% | -2,947,666 (-49.20%) | Filing |
| 2020-07-02 2:59 pm Purchase | 2020-06-15 | 13D | Cardiff Oncology, Inc. CRDF | ACORN BIOVENTURES, L.P. | 5,990,839 9.990% | 4,303,279 (+255.00%) | Filing |